Vetoquinol SA

VETO

Equity

ISIN FR0004186856 / Valor 1393361

Euronext - Euronext Paris (2025-03-13)

EUR 72.00%

Vetoquinol SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Vetoquinol SA is a global company operating in approximately one hundred countries through its subsidiaries and distributors. As an independent, family-owned business, Vetoquinol is dedicated to maintaining strong values and fostering close relationships with veterinary clients. Specializing in animal health products and services, Vetoquinol prioritizes providing high-quality solutions to improve the well-being of animals worldwide.

Summarized from source with an LLMView SourceSector: Technology

Sales Performance

Vetoquinol SA reported sales of €264 million for the first half of 2024, marking a 3.2% increase on a reported basis. The sales of Essential products, which are a key focus for the company, reached €160 million, up 6.0% and accounting for 61% of the Group's total sales during this period.

Net Income and Profitability

The net income attributable to the Vetoquinol Group for the first half of 2024 was €24 million, representing 9.0% of the total sales. This reflects the company's ability to maintain profitability despite challenges in certain markets.

EBITDA and Cash Flow

Vetoquinol's EBITDA for the first half of 2024 stood at €45 million, which is 17.0% of sales. The company also generated a cash flow of €27 million, demonstrating strong financial health and operational efficiency.

Regional Sales Insights

Sales in the Europe strategic territory grew by 5.0% on a reported basis, driven by the performance of Essential products. However, sales in the United States faced challenges, with an 8.7% decline due to inventory reductions at wholesalers and temporary product unavailability.

Outlook and Strategic Focus

Vetoquinol SA remains focused on its development strategy, supported by strong fundamentals such as operating profitability and cash flow generation. The company is well-positioned to finance its external growth ambitions and continue its focus on Essential products to drive future growth.

Summarized from source with an LLMView Source

Key figures

-30.8%1Y

-48.3%3Y

27.2%5Y

Performance

26.0%1Y

31.5%3Y

33.8%5Y

Volatility